Biosapien, Inc.

Biosapien, Inc. , based in the US, specializes in innovative drug delivery systems tailored for cancer treatment, aiming to minimize side effects while maximizing therapeutic effectiveness. Founded in 2018 and headquartered in San Diego, California, Biosapien, Inc. focuses on developing advanced medical technologies.

In July 2025, Biosapien, Inc. raised USD 1 million in pre-series A funding led by Globivest. Biosapien's core product, MediChip™, is a sophisticated drug delivery system aimed at directly targeting tumors, reducing side effects associated with traditional chemotherapy. This technology enables a more precise medication delivery, potentially improving treatment outcomes for cancer patients.

MediChip™ has received global patent protection, facilitating distribution in markets including the US, UK, Europe, Australia, and China, serving a broad spectrum of healthcare providers and patients. The revenue model for Biosapien revolves around the distribution of MediChip™ to healthcare institutions specializing in oncology. Their sales approach includes direct transactions with hospitals and clinics, focusing on personalized treatment plans and potential partnerships that may include subscription services for ongoing support related to the MediChip™ technology. Contracts with healthcare providers are likely to reflect the importance of their product in cancer treatment protocols.

The company plans to use the funding from July 2025 to develop new products, grow its R&D, medical affairs, regulatory, and operations teams, and expand globally.